Editorial

Dolutegravir for second-line treatment: Programmatic implications of new evidence

Ying Zhao, Gary Maartens, Graeme Meintjes
Southern African Journal of HIV Medicine | Vol 23, No 1 | a1428 | DOI: https://doi.org/10.4102/sajhivmed.v23i1.1428 | © 2022 Ying Zhao, Gary Maartens, Graeme Meintjes | This work is licensed under CC Attribution 4.0
Submitted: 06 July 2022 | Published: 05 September 2022

About the author(s)

Ying Zhao, Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Gary Maartens, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; and, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Graeme Meintjes, Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa


Share this article

Bookmark and Share

Abstract

No abstract available.

Keywords

antiretroviral therapy; HIV; dolutegravir; second-line

Metrics

Total abstract views: 396
Total article views: 586


Crossref Citations

No related citations found.